{
    "organizations": [],
    "uuid": "d2c60b607b2e4c4f1d7c288d2b1704f87571cee2",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-catabasis-reports-edasalonexent-pr/brief-catabasis-reports-edasalonexent-preserved-muscle-function-and-substantially-slowed-duchenne-muscular-dystrophy-disease-progression-idUSFWN1Q30ZK",
    "ord_in_thread": 0,
    "title": "Catabasis Reports Edasalonexent Preserved Muscle Function And Substantially Slowed Duchenne Muscular Dystrophy Disease Progression",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 13 (Reuters) - Catabasis Pharmaceuticals Inc:\n* CATABASIS PHARMACEUTICALS REPORTS EDASALONEXENT PRESERVED MUSCLE FUNCTION AND SUBSTANTIALLY SLOWED DUCHENNE MUSCULAR DYSTROPHY DISEASE PROGRESSION THROUGH MORE THAN ONE YEAR OF TREATMENT\n* CATABASIS - PLANS TO INITIATE SINGLE GLOBAL PHASE 3 TRIAL WITH EDASALONEXENT IN PATIENTS WITH DMD REGARDLESS OF MUTATION TYPE IN FIRST HALF OF 2018\n* CATABASIS PHARMACEUTICALS - ‍EDASALONEXENT CONTINUED TO BE WELL TOLERATED WITH NO SAFETY SIGNALS OBSERVED IN TRIAL​\n* CATABASIS PHARMACEUTICALS INC - TOP-LINE RESULTS IN SINGLE GLOBAL PHASE 3 TRIAL WITH EDASALONEXENT IN PATIENTS EXPECTED IN 2020 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-13T21:23:00.000+02:00",
    "crawled": "2018-02-14T12:46:27.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "catabasis",
        "pharmaceutical",
        "inc",
        "catabasis",
        "pharmaceutical",
        "report",
        "edasalonexent",
        "preserved",
        "muscle",
        "function",
        "substantially",
        "slowed",
        "duchenne",
        "muscular",
        "dystrophy",
        "disease",
        "progression",
        "one",
        "year",
        "treatment",
        "catabasis",
        "plan",
        "initiate",
        "single",
        "global",
        "phase",
        "trial",
        "edasalonexent",
        "patient",
        "dmd",
        "regardless",
        "mutation",
        "type",
        "first",
        "half",
        "catabasis",
        "pharmaceutical",
        "continued",
        "well",
        "tolerated",
        "safety",
        "signal",
        "observed",
        "catabasis",
        "pharmaceutical",
        "inc",
        "result",
        "single",
        "global",
        "phase",
        "trial",
        "edasalonexent",
        "patient",
        "expected",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}